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Analysis of the cross-talk of Epstein–Barr virus-infected
B cells with T cells in the marmoset
Jordon Dunham1,2, Nikki van Driel1, Bart JL Eggen2, Chaitali Paul2, Bert A ‘t Hart1,2, Jon D Laman2,3
and Yolanda S Kap1,3
Despite the well-known association of Epstein–Barr virus (EBV), a lymphocryptovirus (LCV), with multiple sclerosis, a clear
pathogenic role for disease progression has not been established. The translationally relevant experimental autoimmune
encephalomyelitis (EAE) model in marmoset monkeys revealed that LCV-infected B cells have a central pathogenic role in the
activation of T cells that drive EAE progression. We hypothesized that LCV-infected B cells induce T-cell functions relevant for
EAE progression. In the current study, we examined the ex vivo cross-talk between lymph node mononuclear cells (MNCs) from
EAE marmosets and (semi-) autologous EBV-infected B-lymphoblastoid cell lines (B-LCLs). Results presented here demonstrate
that infection with EBV B95-8 has a strong impact on gene expression proﬁle of marmoset B cells, particularly those involved
with antigen processing and presentation or co-stimulation to T cells. At the cellular level, we observed that MNC co-culture
with B-LCLs induced decrease of CCR7 expression on T cells from EAE responder marmosets, but not in EAE monkeys without
clinically evident disease. B-LCL interaction with T cells also resulted in signiﬁcant loss of CD27 expression and reduced
expression of IL-23R and CCR6, which coincided with enhanced IL-17A production. These results highlight the profound impact
that EBV-infected B-LCL cells can have on second and third co-stimulatory signals involved in (autoreactive) T-cell activation.
Clinical & Translational Immunology (2017) 6, e127; doi:10.1038/cti.2017.1; published online 10 February 2017
Epstein–Barr virus (EBV), a causative agent of classical infectious
mononucleosis, is a γ1-herpes virus and the human representative
among a larger group of primate lymphocryptoviruses (LCVs).1,2
Despite numerous lines of evidence indicating an association
between EBV and autoimmune conditions such as multiple
sclerosis (MS), an exact pathogenic role in autoimmune diseases is
unclear.3 As non-human primates are naturally infected with EBV-
related LCV, they provide potentially relevant animal models in
which the relationship between EBV and autoimmunity can be
explored. The experimental autoimmune encephalomyelitis (EAE)
model in common marmosets (Callithrix jacchus) is a translation-
ally relevant model of the autoimmune neurological disease
MS.4 The common marmoset is also host to a B-cell transforming
lymphocrypto/γ1-herpes virus, CalHV-3 (callithrichine herpes
virus 3), which is considered to be homologous to EBV.5 Via
reverse translation analysis of therapies that did (anti-CD20
monoclonal antibodies (mAbs))6 or did not (atacicept)7 show a
beneﬁcial effect in MS clinical trials, we discovered a new
pathogenic role of B cells in the activation of myelin oligoden-
drocyte glycoprotein (MOG)-speciﬁc T cells in this model.8 In
brief, we discovered that the opposite clinical effect of these
treatments might be explained by the differential depletion of
B cells infected with CalHV-3.9 These and other ﬁndings led us to
postulate that LCV-infected B cells have a core pathogenic
role in the marmoset EAE model that is endowed by the virus
infection.10
The aim of the current study was to gain deeper insight into the
cross-talk between LCV-infected B cells and autoreactive T cells
isolated from marmosets sensitized against MOG34–56 formulated
with the mineral oil incomplete Freund’s adjuvant (IFA). This
formulation induces a progressive MS-like disease characterized by
MS-like pathology in the white and cortical gray matter of brain and
spinal cord.11,12 We ﬁrst analyzed using RNAseq which B-cell genes
relevant for T–B communication were expressed at higher level after
LCV infection. For these experiments, we used EBV from the cell line
B95-8. In addition, we tested the role of several receptor–ligand pairs
using mAbs.
The results demonstrate that interactions between LCV-infected
B cells and lymph node-derived T cells from MOG34–56/
IFA-immunized marmosets lead to profound phenotypic altera-
tions of T cells. These data may be interpreted as an attempt
of the EBV-infected B cells to escape the immune system by
phenotypically altering the T cells in critical markers related to
homing, Th17 responses, development and function that may
partially explain the temporal association between EBV and
autoimmune diseases.
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BLCL vs CD20+ top up-regulated enriched pathways
Name Number of Genes P Value
Pathways in cancer 45 6,97E-4
Cytokine-cytokine receptor interaction 34 1,32E-4
MAPK signaling pathway 34 0,002
Focal adhesion 27 0,004
Regulation of actin cytoskeleton 25 0,019
BLCL vs CD20+ top down-regulated enriched pathways
Name Number of Genes P Value
Chemokine signaling pathway 26 9,25E-4
Cytokine-cytokine receptor interaction 26 0,005
Hematopoietic cell lineage 24 8,51E-9
Neuroactive ligand-receptor interaction 24 0,068
MAPK signaling pathway 24 0,083
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RESULTS
EBV infection of B cells alters stimulation signals to T cells
RNA sequencing was used to determine the impact of EBV infection
on marmoset B cells (B-lymphoblastoid cell line, B-LCL) gene
expression in comparison to spleen-derived CD3−CD20+ B cells. A
principle component analysis was performed to determine the
similarity between biological replicates and differences between
samples conditions (data not shown). A differential gene expression
analysis was performed to determine the genes that were differentially
expressed between B-LCLs and CD20+ B cells and to identify pathways
and overrepresented categories (Figure 1). In total, LCV infection
resulted in increased expression of 2860 genes (false discovery rate
(FDR)o0.05; logFC4+1) and reduced expression of 2608 genes
(FDRo0.05; logFCo− 1). Shown in the table of Figure 1b is a list of
top upregulated and top downregulated enriched pathways. As could
be expected, we also observed a clear enrichment of cell cycle-related
genes, and altered the expression of apoptosis genes, which is
consistent with the fact that B-LCLs are immortalized lines (data
not shown).
We were particularly interested in the expression of genes related to
T-cell activation to determine how EBV inﬂuences antigen-presenting
cell (APC) functions of B cells. We observed differential expression of
many genes related to antigen presentation and processing pathways,
particularly those of co-stimulation and peptide processing (Figure 1).
Shown in Figure 1 is a heatmap of differentially expressed genes
related to antigen presentation/co-stimulation, with noted upregula-
tion in critical surface markers such as CD70, CD80, CD86, PCDC1
(PD-1) and both FAS (CD95)/FASL (CD95L) being observed.
Furthermore, expression of a number of genes involved in peptide
processing via the vacuolar route (endolysosomes) and the cytosolic
route (proteasomes) was profoundly impacted (Figure 1). Shown in
Supplementary Table 1 is a list of gene descriptions and fold changes
of all presented genes selected for the heatmap of Figure 1a.
Interestingly, expression of MR1, a receptor involved in the activation
of mucosal-associated invariant T cells (MAIT) by presentation of
metabolites of vitamin B,13 was also strongly upregulated in B-LCLs
(data not shown).
Collectively, this RNA sequencing data highlights how LCV infec-
tion induces a unique transcription proﬁle that is markedly different
from non-infected CD20+ B cells. This unique transcript proﬁle, with
enhanced expression of key co-stimulatory molecules and altered
proteasome and endolysosome function, indicates that the LCV-
infected B cell is an atypical APC. Of note, LCV infection also endows
B cells with the ability to rescue proteolysis-sensitive self-antigens from
destructive processing via citrullination as previously demonstrated,14
which may be involved in the association between autoimmune
disease and progression of primate EAE.
A dichotomous inﬂuence of B-LCL on T-cell homing receptor CCR7
Previous reports implicating the CalHV-3+/EBV-infected B cell as the
license for T-cell egression from the lymph node warrant further
investigation.15 Here we assessed the effect of B-LCLs on the
expression of CCR7, which was previously known as EBV-induced
molecule 1 and is a vital receptor in controlling the dynamic lym-
phocyte homing towards secondary lymphoid organs (SLOs).16–18
Overall, B-LCLs had no consistent effect on CCR7 expression on
CD4+ or CD8+ T-cell subsets in either CD45RA− memory cells or
CD45RA+ naive cells (Figure 2a). As we noticed reduced expression of
CCR7 in some animals, we analyzed the data based on whether the
mononuclear cell (MNC) donor animals had developed clinically
evident EAE. Indeed, co-culture with B-LCLs induced signiﬁcant
reduction of CCR7+ T cells in MNC isolated from animals that
had developed clinically evident EAE (score X 2.5), whereas no effect
was observed on the percentage of CCR7+ T cells in MNC isolated
from marmosets that failed to develop clinically evident EAE
(Figure 2b).
Reductions in CCR7 were observed in the presence or absence of
MOG34–56, indicating that the effect is independent of antigen
recognition (Figure 2a). Moreover, a similar effect was observed in
CD4+ and CD8+ T cells irrespective of the expression of CD45RA,
indicating that this effect is not restricted to effector, memory or naive
populations (Figure 2b).
B-LCLs induce profound reduction of CD27 expression and alter
Th17 responses
EBV infection induced profound changes in the expression of
co-stimulatory molecules by B cells. One peculiar, and often over-
looked, feature of EBV-infected B cells is an enriched expression of
CD70.19 Similar to human B-LCLs, marmoset B-LCLs exhibit elevated
expression of CD70 compared to non-infected CD20+ primary B cells
(Figure 1). We investigated whether increased expression of CD70
would alter the expression of its counter-structure CD27 on marmoset
T cells as was previously reported for human cells.20 Indeed,
interaction with EBV-infected B-LCLs had a profound impact on
the expression of CD27, both on CD4+ and CD8+ T cells (Figure 3).
This effect was irrespective of MOG34–56 and not constrained to
CD45RA expression, suggesting that this effect is not speciﬁc for only
memory or naive T cells. In addition, cell–cell contact was essential as
in the transwell cultures no reduction of CD27 was observed
(Figure 3). As a control, we also analyzed cellular phenotypes at time
point 0 h, where B-LCLs and MNCs were immediately processed for
staining upon co-culture. Reductions in CD27 expression were
observed within minutes after B-LCLs and MNCs were encountered,
indicating that this phenomenon can also occur without extensive
rounds of cell division or chronic stimulation (Figure 3).
The intrinsic importance of the tumor necrosis factor receptor
family member CD27 in the induction of Th17 responses has recently
Figure 1 EBV infection alters critical markers involved in antigen presentation and co-stimulation of the B cell. RNA sequencing was performed on spleen-
derived CD3−CD20+ B cells from immunologically healthy marmosets (n=2) and marmoset B-LCLs (n=2), with 10 million high-quality uniquely mapped
reads were obtained per sample, to determine the effect of EBV infection on gene expression involved in antigen presentation and co-stimulation pathways.
EBV infection resulted in differential expression (FDRo0.05, logFC=±1) in pathways associated with cell growth/survival functions, metabolic processes and
antigen presentation/co-stimulation. (a) Shown is a heatmap depicting genes associated with the selected categories antigen presentation, lysosome and
proteasome (processing) function chosen from the list of differentially expressed genes. Tabular data for these genes are in Supplementary Table 1. The
scaled expression value (Z score) is displayed in red-green color scheme with red indicating lower expression and higher expression in green. (b) Depicted are
the top ﬁve up- and downregulated pathways.
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been detailed.21 We therefore assessed CCR6, IL-23R and Th1/Th17
cytokine expression following exposure to the B-LCLs (Figure 4).
Signiﬁcantly reduced expression levels of both CCR6 and IL-23R were
found on CD4+ and CD8+ subsets of CD27− cells (Figures 4a and b).
This effect was observed regardless of CD45RA expression (data not
shown), and was not dependent on the presence of the MOG34–56
peptide. Although we did not observe impacts on IL-23R expression at
early time points (data not shown), signiﬁcant reductions of CCR6
expression on CD27− T cells were observed shortly after cells were
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Supernatants of co-cultures of MNC with B-LCL in the presence or
absence of MOG34–56 were analyzed for secreted cytokines. Negli-
gible production of IL-23p19, IL-12p70 and IL-2 was observed after 24
and 48 h incubation (data not shown). Interestingly, although reduc-
tions of CD27, CCR6 and IL-23R in co-cultures were observed
regardless of addition of MOG34–56 (Figures 4a and b), the addition
of B-LCLs and MOG34–56 to MNCs elicited signiﬁcantly higher levels
of IL-17A than in MNC cultures with only B-LCL or MOG34–56
(Figure 4c). The addition of B-LCLs with MOG34–56 also elicited
signiﬁcant increase of IFN-γ production compared to MOG34–56
stimulated MNCs without B-LCLs (Figure 4c). These effects were
mitigated with transwell separation showing that direct cell–cell
contact and antigen recognition are both required for cytokine
production despite observations of changes at the surface marker level.
Modulation of CD127 and CD95 is mediated by cell–cell contact
and not by IL-7 secretion
It has been demonstrated that EBV-transformed human B-cell lines
constitutively secrete the cytokine IL-7 and express CD95L (FasL).22,23
Our own data also indicate that marmoset B-LCLs express CD95L
(Figure 1a), and that the IL-7/CD127 pathway has been implicated in
marmoset EAE progression.24 A relationship between IL-7 and CD95
(Fas) expression has been established25,26 and because of these data,
we hypothesized that co-culture with the B-LCLs affects both IL-7R
(CD127) and CD95 expression on T cells. We observed profound
reductions of CD127 both in CD4+ and CD8+ populations. The
reduction of CD127 occurred regardless of CD45RA expression in
CD4+ T cells, but was not observed in CD45RA-expressing cells
in the CD8+ compartment (Figure 5a). The addition of antigen
(MOG34–56) resulted in more profound reductions in CD4-
expressing T cells, and was a requirement for CD127 reductions in
CD8-expressing T cells (Figure 5a). Reductions of CD127 depended
on physical contact between B-LCLs and T cells, indicating that
reduced detection of CD127 was not cytokine mediated or due to
receptor occupancy by constitutively secreted IL-7.
The addition of the B-LCLs led to signiﬁcantly increased CD95
expression in CD45RA-expressing CD4+ and CD8+ T cells, but only
had a negligible impact on CD95 expression by CD45RA− T cells
(Figure 5b). Unlike CD127, altered expression of CD95 was not
strongly inﬂuenced by addition of antigen to the culture. No
alterations in the expression of CD127 or CD95 were observed
when the B-LCLs and T cells were physically separated by porous
polyethylene terephalate membranes, which would allow diffusion of
cytokines from the top to bottom chambers (Figures 5a and b).
B-LCL stimulates profound expression of CD279 (PD-1)
The data discussed thus far demonstrate that T-cell exposure to B-LCLs
alters the expression of a variety of factors, many of which are not
restricted by the addition of MOG34–56 antigen and which are induced
by the contact with B-LCLs. Cells chronically infected with herpes virus
(cytomegalovirus (CMV) and EBV) and malignant cells employ
mechanisms of immune evasion, such as alterations in the CD279/
CD274 signaling pathway and the interaction of CD70 with CD27.27,28
In mouse melanoma models, anti-CD27 treatment correlated to lower
CD279 expression on CD8+ T cells. On the other hand, overexpression
of CD70 in dendritic cells is sufﬁcient to break CD279 (PD-1)-mediated
tolerance in ovalbumin-immunized CD11c-CD70tg mice.29–31
We assessed the expression of CD279 on T cells upon co-culture
with B-LCLs. Shown in Figure 6 is the signiﬁcant increase in the
percentage of T cells expressing CD279. Upregulation of PD-1
expression was observed regardless of CD45RA expression in both
CD4 and CD8-expressing T cells on this parameter. Moreover,
addition of MOG peptide in co-culture conditions only had a minor
effect. Despite previous associations between CD27/CD70 and PD-1
expression, CD279 increase was not restricted to CD27− T cells and
thus no relationship between CD279 and CD27 expression was
observed in this system (data not shown).
T cells acquire APC-associated co-stimulatory markers
During the cognate interaction of T cells with malignant cells,
membrane patches can be exchanged, a phenomenon known as
trogocytosis. As an example, trogocytosis drives the acquisition of
CD86 and HLA-G by T cells as an immune evasive mechanism in
multiple myeloma patients.32 We examined whether evidence for
trogocytosis could be found in the interaction of T cells with B-LCLs
from marmosets and whether this may explain the acquisition
by T cells of CD86 observed in longer co-culture experiments
(own unpublished data). Shown in Figure 7 is the expression of
co-stimulation molecules of APCs (CD80, CD86 and CD40) on CD4+
and CD8+ T cells following a 3 h co-culture with B-LCLs. Interest-
ingly, we observed only transfer of CD40 and CD86, not of CD80.
Moreover, this effect was, in part, mitigated by the addition of MHC I
and II blocking antibodies and completely mitigated by physical
separation in a transwell system. Acquisition of co-stimulatory signals
via trogocytosis was observed in both CD4+ and CD8+ T-cell subsets
(Figure 7). The absence of detectable CD80 transfer may be an artifact
of time point measured.33 Unfortunately, technical limitations with
ﬂuorescence-activated cell sorting (FACS) sorting marmoset cells of
high viability and the very limited cell number available for assays
precluded further exploration of the functionality of this
phenomenon.
DISCUSSION
A mechanistic explanation for the well-documented serological and
epidemiological link between EBV and MS34–36 eludes scientists
studying the immunobiology of MS risk factors. Research in a
translationally relevant non-human primate model for MS, EAE in
common marmosets, demonstrated a central pathogenic role of
Figure 2 A dichotomous effect of B-LCLs on T-cell homing receptor CCR7. Mononuclear cells derived from the axillary lymph nodes (LNs) of marmosets
(n=14) immunized with MOG34–56/IFA were co-cultured with CellTrace-labeled B-LCLs with or without the addition of MOG34–56 for 48 h. A transwell
system in which B-LCLs and LNs were separated was used as a control (no MOG34–56 was added). Expression of T-cell homing receptor CCR7 was analyzed
by ﬂow cytometry following exclusion of CellTrace-labeled B-LCLs and dead cells. Lymphocytes were selected based upon forward scatter/side scatter
selection and T-cell subsets were identiﬁed for the expression of CD3+, CD4+ or CD8+ and CD45RA+/− . Data are presented as % CCR7-expressing cells from
the parent gate indicated above or below the graphs. (a) Co-culture with B-LCLs had no overall effect on the percentage of CD3+CD4+CD45+/− and CD3+
CD8+CD45+/− cells expressing CCR7. (b) When data were analyzed based upon clinically evident EAE (EAE+) in comparison to monkeys that failed to
develop EAE (EAE−), a reduced expression of the percentage of CD3+CD4+CD45+/− and CD3+CD8+ CD45+/− cells expressing CCR7 was observed in
co-cultures of EAE+ animals. Reductions in CCR7+ T cells in EAE+ monkeys were not restricted to CD45RA− (memory cells) or CD45RA+ (effector cells), and
did not require MOG34–56 stimulation. Statistical signiﬁcance (Po0.05) is indicated by an asterisk, signiﬁcance of Po0.01 is indicated by **.
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LCV-infected B-LCL (review37). This was concluded, among others,
from the distinct clinical effect of therapeutic anti-CD20 mAbs versus
mAbs against the B-cell growth and differentiation factors BLyS/BAFF
and APRIL, which could be explained by differential depletion of the
LCV-infected B-cell subset.38 Follow-up studies demonstrated that
B-LCLs have a crucial role in the immune mechanisms driving EAE
progression, namely, the activation and licensing for SLO egression of
the autoreactive T cells and cross-presentation of self-antigen to auto-
aggressive cytotoxic T lymphocyte (CTL).15 The current study was
undertaken to gain further insight into messages exchanged in the
ex vivo cross-talk between B-LCLs and (autoreactive) T cells.
We ﬁrst examined the effect of EBV infection on the expression of
B-cell genes relevant to T-cell activation and potentially involved in the
cognate interaction with the T cell. In addition, we performed ex vivo
co-culture assays with MNCs isolated from the SLO of MOG34–56/
IFA-immunized marmosets and EBV-infected B-LCL generated prior
to induction of EAE. Assays were performed in the presence and
absence of the immunizing MOG34–56 peptide to be able to
distinguish general effects on T cells from those exchanged in the
cognate interaction between B-LCLs and autoreactive T cells.
The concept that LCV-infected B cells act as professional APCs
for the pathogenic T cells is in itself a paradox. It implies that the
infected B cells simultaneously trigger a T-cell response against the
immunizing peptide MOG34–56 as well as avoid detection by anti-
viral T cells for escaping a cytotoxic response. RNA sequencing data
presented here demonstrate that the expression of many key genes
involved with communication to the T cell is altered upon infection
with LCV. Another explanation may be the observation that the
autoreactive T cells recognize the epitope MOG40–48 of the auto-
aggressive CTL in the context of major histocompatibility complex
(MHC) class I/Caja-E molecules.39 MHC-E molecules have a well-
documented role in immune escape from herpes virus-infected T
cells.40 This dual role of MHC-E depends on the type of the peptide
bound in the cleft, which directs interaction either to stimulatory
CD94/NKG-2C or inhibitory CD94/NKG-2A complexes.41
Evidence suggests that one of several contributions of the B-LCL in
EAE progression is the activation and licensing for SLO egression of
the (autoreactive) T cells.15 Binding of chemokines such as CCL19 and
CCL21 to CCR7 directs T-cell homing to SLO and reduction in CCR7
expression gives T cells the license to egress from SLO, after which
they can migrate to their target organ. These data, in scope of previous
reports using B-cell depletion with clinically relevant mAbs (ofatu-
mumab and belimumab), support a role of the LCV-transformed B












































































































































Figure 3 Tumor necrosis factor family member CD27 is lost after co-culture. Mononuclear cells derived from the axillary lymph nodes (LNs) of marmosets
(n=14) immunized with MOG34–56/IFA were co-cultured with CellTrace-labeled B-LCLs with or without the addition of MOG34–56 for 48 h. A transwell
system in which B-LCLs and LNs were separated was used as a control (no MOG34–56 was added). Shown is the percentage of CD27-expressing cells
within the parent gate indicated above the graphs. The percentage of CD27-expressing cells was severely reduced upon co-culture with B-LCLs (48 h). This
was irrespective of naive or effector status or addition of MOG34–56 and already occurred at 0 h measurement for memory (CD45RA−) cells as denoted by
0 h bar. Statistical signiﬁcance of Po0.05 is indicated by an asterisk, signiﬁcance of Po0.01 is indicated by **, signiﬁcance of Po0.001 is indicated
by ***.
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Figure 4 B-LCLs modulate Th17 responses. The effect of B-LCLs on Th17 responses was analyzed by classic Th17-associated markers by FACS and with the
ProcartaPlex Luminex assay. Mononuclear cells derived from the axillary lymph nodes (LNs) of marmosets (n=14) immunized with MOG34–56/IFA were
co-cultured with CellTrace-labeled B-LCLs with or without the addition of MOG34–56 for 48 h. A transwell system in which B-LCLs and LNs were separated
was used as a control (no MOG34–56 was added). Supernatant was collected to measure cytokine production and cells were analyzed by FACS. Shown is
the percentage of cells expressing either IL-23R (a) or CCR6 (b) from the parent gate indicated above the graphs. (a and b) Reductions in the percentage of
IL-23R- and CCR6-expressing CD4+ and CD8+ T cells were observed in cells that had lost CD27 expression. In both cases, the addition of antigen was not
required for reductions, and not limited to effector populations (data not shown). (b) Reductions in CCR6 were observed at initial co-culture periods (0 h)
taken for baseline measurements. (c) Stimulation of B-LCL and antigen elicited signiﬁcantly higher levels of IL-17A and IFN-γ compared to their respective
controls following 48 h of co-culture. Secretions of both cytokines were dependent upon the addition of antigenic peptide. Detection of IL-23p19, IL-12p70
and IL-2 was absent after 24 and 48 h (data not shown). Statistical signiﬁcance of Po0.05 is indicated by *, signiﬁcance of Po0.01 is indicated by ** and
Po0.001 is indicated by ***.
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show here downregulation of the SLO homing receptor CCR7 by
B-LCL only in T cells from clinical EAE responder marmosets (EAE
score ⩾ 2.5) indicating that the downregulation of CCR7 may be a
rate-limiting step in the pathogenic process. Another explanation for
this phenomenon would be that T cells from marmosets with clinically
evident EAE have enhanced activity or an altered activation state.
However, this dichotomous response to B-LCLs was not observed for
the other markers analyzed in the current study.
EBV-speciﬁc human T cells express CD27 and homozygous
mutations in CD27 resulting in CD27 deﬁciency are associated with
persistent EBV viremia, suggesting that the CD27/CD70 axis plays an
important role in the control of EBV infection.42,43 It is well possible
that the high CD70 expression by the EBV B-LCLs, which is
conﬁrmed by our RNAseq data, supports immune escape, as seen in
human glioblastomas and in lymphoproliferative diseases.44 Other
evidence indicates that the CD27/CD70 pathway plays an important
pro-pathogenic role in autoimmune conditions. Ligation of CD70 to
CD27 induces release of soluble CD27 (sCD27) and it is indeed
interesting that increased soluble CD27 level is a hallmark of diverse
autoimmune conditions with a strong link to EBV, such as in
cerebrospinal ﬂuid in MS, in synovial tissue in RA and in serum in
both systemic lupus erythematosus and Sjögren’s syndrome.22,45–48
We propose that the elevated CD70 expression is an important,
overlooked feature of EBV-infected B cells and that the CD27/CD70
axis may be relevant in the association between EBV and MS.
The observation that B-LCLs pulsed with MOG34–56 induce
IL-17A is interesting, as the reduction of CD27, CCR6 and IL-23R
occurred independent from addition of the immunizing peptide. This
ﬁnding may indicate that physical interaction between B-LCLs and
T cells is sufﬁcient to alter surface markers expression on the T cell,
whereas presentation of the antigenic peptide was required to elicit a
functional response, that is, expression of IL-17A, which is the
cytokine signature of the EAE model induced with MOG34–56/
IFA.11
The here-reported data show that cross-talk with B-LCLs induces
enhanced PD-1 expression on T cells. This is potentially relevant for
MS, regarding the well-documented role of PD-1 and its ligand PD-L1


































































































































Figure 5 Modulation of CD127 and CD95 is mediated by cognate B–T interaction and not by IL-7 secretion. (a) Co-culture of mononuclear cells (MNCs)
from axillary lymph node (LN; n=14) with B-LCLs resulted in minor reductions in the percentage of CD3+CD4+/CD8+CD45RA+ cells expressing CD127
(IL-7R). Reductions were greater with the addition of antigen (MOG34–56). This effect was also observed in memory subset (CD45RA−) in CD4+ T cells,
but not CD8+ T cells. Physical separation of cell populations by porous membrane, that would enable cytokine diffusion, mitigated reductions of CD127.
(b) B-LCLs induced a signiﬁcant increase in the expression of CD95 in effector and naive (CD45RA+) T-cell populations, but less so in memory subsets. In
naive and effector populations, this effect was not restricted to CD4/CD8 expression, did not require antigen stimulation and was also mitigated by transwell
system. Statistical signiﬁcance of Po0.05 is indicated by *, signiﬁcance of Po0.01 is indicated by ** and Po0.001 is indicated by ***.
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suggested and supported by evidence that autoimmune disease results
from a general dysfunction of immune homeostatic mechanisms and
peripheral tolerance breakdown.49 There is an established correlation
between EBV viral load in acute infectious mononucleosis and PD-1
expression. Furthermore, the PD-1/PD-L1 pathway is altered in MS
and elevated PD-1/PD-L1 expression has been associated with disease
remission in MS patients.50,51 It is tempting to speculate that
repetitively enhanced expression of PD-1 (that is, receptor exhaus-
tion), possibly as an immune escape mechanism for B-LCLs, would
have consequences for subsequent PD-1 functionality or expression.
Our results conﬁrm previous reports showing enhanced expression
of CD95 in response to B-LCLs.52 In murine transgenic systems,
CD27–CD70 interactions sensitize T cells for CD95-mediated
apoptosis.53 Elevated expression of CD95L, a feature of marmoset
B-LCL, has also been shown to upregulate CD95 expression. Although
the B-LCLs constitutively secrete IL-7, and IL-7 has been shown to
upregulate CD95 expression, altered expression of CD95 was depen-
dent on cell–cell contact in our test system. Hence, the effect may be
mediated through CD70 and/or CD95 stimulation. Given the biolo-
gical importance of the CD95/CD95L pathway in the containment of
T-cell responses, any alteration of this pathway has potential relevance
to MS. The T-cell CD95/Fas function is dysregulated in the MS patient
with increases in soluble CD95 in relapsing remitting MS and elevated
CD95L expression in inﬂammatory inﬁltrates in both active and
chronic lesions.54,55 It may be that modulation of CD95 is just
representative of activation, or possibly suppression through apoptosis,
as previously suggested.23 The biological plausibility of this association
is not a leap as one hallmark of acute infectious mononucleosis is
enhanced CD95 and CD95L expression.52,56
The current study also shows expression of co-stimulatory mole-
cules of APC on T cells, CD40 and CD86, at much earlier time points
than shown by others. This effect may be attributable to the transfer of
membrane patches during cognate interaction of APCs and T cells, a
phenomenon known as trogocytosis.57,58 Although we did not observe
CD80 transfer, this could be a kinetics issue as previously noted.33 It
has been shown that EBV utilizes trogocytosis as a strategy to endow
cells with receptors important for viral transmission. However, the
functional signiﬁcance of trogocytosis itself is debated and suggested
effects seem wide-ranging; implication of potential regulatory effects
on the T cell of the MS patient warrant further investigation.59,60 The
transfer of CD40 in particular is interesting given the importance of
CD40 in functional CD8 T-cell responses (that is, cytokine secretion
and proliferation), and evidence suggesting that these CD4–CD8
collaborations can be dissociated from APC help; acquisition of
CD40 by CD8+ T cells could allow CD4 cells to directly help CD8
cells via CD40–CD40L interaction.58 Moreover, recently it has been
observed that a subset of CD4+ T cells expressing CD40 are expanded
in MS and serve as a new biomarker for disease.61
In conclusion, we propose that the LCV-infected B cell may play a
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by enhanced expression of co-stimulatory markers such as CD70 and
CD95L. Correlations between multiple autoimmune diseases, a lack of
identiﬁcation of EBV in disease-speciﬁc target tissues and temporal
relationship between elevated levels of EBV in relation to disease
activity provide strong arguments for this line of thinking. Although it
could be argued that EBV infection is a by-product of abnormal
dysfunctional immune responses due to disease activity, these results
highlight the profound impact B-LCL (that is, constitutively CD70-
and CD95L-expressing APCs), can have on the SLO-derived T cell.
This study demonstrates that EBV infection of the B cell alters the
normal communication process between the T and B cell, and
highlights potential roles in T-cell egression and activation and Th17
responses. Future investigations of these pathways in MS-derived




Consistent with the 3R principles of animal experimentation, this research was
performed with surplus cells from scheduled EAE studies in which the efﬁcacy
of new therapies was tested. Due to the limited number of cells available from
some marmosets, not all assays could be performed for all individuals.
Marmosets treated with pharmacological agents were included in this study
only after individual analysis of data found no discrepancies between placebo
and treated animals. MNCs isolated from axillary lymph nodes (ALNs) were
obtained from 14 adult (female, age ranging between 2 and 5 years) common
marmosets (Callithrix jacchus) enrolled in EAE studies. All marmosets were
acquired from the purpose-bred colony at the BPRC (Rijswijk, Netherlands)
and declared in good health by veterinary staff prior to enrollment into the
study. Health checks included physical examination and tests for hematological,
serological and microbiological abnormalities.
The used EAE model was induced with a synthetic peptide representing
residues 34–56 of human MOG (MOG34–56; Cambridge Research Biochem-
icals Ltd, Cleveland, UK, sequence=GMEVGWYRPPFSRVVHLYRNGKD)
emulsiﬁed with IFA (Difco Labs, Detroit, MI, USA) as previously
described.62
Ethics
The EAE experiments from which MNC were derived for this research were
reviewed and approved of by the Institute’s Animal Ethics Committee.
Marmosets were housed and handled according to the Dutch Law on animal
experimentation. The animal facilities of BPRC have been inspected and









































































































































Figure 6 B-LCL rapidly alters CD279 (PD-1) expression in T-cell subsets. Expression of CD279 (PD-1) on MNC-derived T cells (n=14) was analyzed by ﬂow
cytometry following co-culture with B-LCLs. The ﬁgure depicts percentages of CD3+CD4+CD45RA+/− (top panel)- and CD3+CD8+CD45RA+/− (bottom panel)-
expressing CD279. In all T-cell subsets examined following 48 h of co-culture, profound increases in the percentage of CD279+ cells were observed. In
earliest time points measured (0 h) taken for calibration purposes, whereby cells were co-cultured and immediately centrifuged and stained for FACS,
expression of CD279 was also increased in either CD4 or CD8 T-cell subsets expressing CD45RA. Statistical signiﬁcance of Po0.05 is indicated by *,
signiﬁcance of Po0.01 is indicated by ** and Po0.001 is indicated by ***.
EBV-infected B cells alter T-cell responses
J Dunham et al
10
Clinical & Translational Immunology
Generation of EBV-infected B-LCLs
The B95-8 EBV strain, henceforth indicated as EBV, was isolated from a human
with infectious mononucleosis and has been maintained for decades in
marmoset lymphocytes.63 The virus infects human and marmoset B cells,
providing a well-established and frequently used experimental model of EBV
infection.
Four weeks prior to the start of the EAE studies B-LCLs were generated by
the infection of blood MNCs with human EBV B95-8.62 Brieﬂy, peripheral
blood mononuclear cells were cultured with supernatant from the EBV-
producing B95-8 cell line for 1.5 h at 37 °C. Following incubation, cells were
diluted at a 1:1 ratio with RPMI-1640 (Gibco Life Technologies, Bleiswijk
Netherlands) culture medium containing 1 μg ml− 1 phytohaemagglutinin and
supplemented with 10% v/v heat-inactivated fetal calf serum (Gibco), 2.0 mM L-
alanyl-L-glutamine (Gibco) and 50.0 U ml− 1 penicillin/streptomycin (Gibco).
Following successful transformation, cells were maintained in culture medium
without phytohaemagglutinin until further use. Cells were mycoplasma
negative and exhibited no irregularities.
Co-culture of MNCs with EBV-infected B cells
At necropsy of MNC donors, the (semi-) autologous B-LCLs were collected
from culture, irradiated at 50 Gy to prevent proliferation and stained with
1.0 μM CellTrace Violet (Molecular Probes, Eugene, OR, USA) for ﬂow
cytometric identiﬁcation. B-LCLs were mixed with MNCs (n= 14) from the
ALN (1:1) and incubated in RPMI-1640 (Gibco) culture media supplemented
with 10% v/v heat-inactivated fetal calf serum, L-alanyl-L-glutamine (Gibco)
and penicillin/streptomycin, and cells were plated directly in 96-well V-bottom
plates for initial (0 h) ﬂow cytometric analysis or in 24-well plates for longer
incubation periods (48 h). Blocking of marmoset MHC molecules was
performed with mAbs directed against human MHC class II (clone PDV5.2)
and MHC class I (clone W6/3) at 1:100 ascites dilution after which cells were
pulsed with MOG34–56 peptide.
Polyethlene terephalate cell culture inserts (1 μm pore; BD Falcon, Bedford,
MA, USA) were used for transwell culture conditions, whereby B-LCLs and
MOG34–56 were loaded into the top chamber, and MNCs were loaded into the
bottom chamber (1:1). Flow cytometric-based assays for detecting trogocytosis
were performed with 3 h co-culture periods and utilized MHC blocking and
transwell systems as described above.
Cellular phenotyping
MNCs were phenotyped by ﬂow cytometry as previously described.62 Brieﬂy,
cells were stained with an LIVE/DEAD Fixable Aqua Dead Cell Stain
(Invitrogen, Molecular Probes, Carlsbad, CA, USA) for 25 min at room
temperature to exclude dead cells. An FcR blocking reagent was used to block
nonspeciﬁc antibody staining (Miltenyi Biotec, Bergisch Gladbach, Germany).
Subsequently, cells were stained with commercially available mAbs against































































































































































































































































































































Figure 7 B-LCL-mediated T-cell acquisition of APC markers. Short-term co-cultures of mononuclear cells derived from the axillary lymph nodes (LNs) of
marmosets (n=14) immunized with MOG34–56/IFA with B-LCLs (3 h) resulted in detection of CD86 and CD40 expression, but not CD80, on both CD4
(top panel) and CD8 (bottom panel) T-cell populations. This effect required cognate interaction between B-LCLs and T cell as the addition of antibodies to
block of MHC class I and MHC class II signiﬁcantly reduced detection of both CD86 and CD40. Statistical signiﬁcance of Po0.05 is indicated by *,
signiﬁcance of Po0.01 is indicated by ** and Po0.001 is indicated by ***.
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(NCAM 16.2), CD80 (L307.4), CD86 (IT2.2) and HLA-DR (L243; all from BD
Biosciences, San Diego, CA, USA); CD279 (J105) and CD127 (ebioDR5) (both
from Ebioscience, San Diego, CA, USA); IL-23R (218213), CCR6 (53103) and
CCR7 (150503) (all from R&D systems, Minneapolis, MN, USA); CD20 (H299,
Beckman Coulter, Pasedena, CA, USA); and CD8 (LT-8, Serotec, Dusseldorf,
Germany). Cells were ﬁxed in 1% cytoﬁx (BD Biosciences) prior to
measurement.
Flow cytometric measurements were performed utilizing the FACS LSRII
ﬁtted with FACSDiva 5.0 (BD Biosciences) and data were analyzed with FlowJo
software (Treestar, Ashland, OR, USA). The gating strategy to determine
phenotype and exclude B-LCLs in analysis was as follows: ﬁrst, B-LCL was
excluded by gating CellTrace-negative cells (=MNC). Next, lymphocytes were
identiﬁed based on forward scatter and side scatter. Live cells were then selected
as aqua viability stain negative cells. Within the living lymphocyte population
T cells were selected based on the expression of CD3. Within the CD3+ T-cell
population, CD4+CD8− and CD4−CD8+ cells were distinguished. Within
these subpopulations, additional markers, such as CD27 and CD45RA, were
analyzed. Data in ﬁgures are presented as a percentage of the previous identiﬁer
gate. B-LCL controls were stained with CD3 and CD4/CD8, and gated as
mentioned above, to ensure purity of analyzed T cells.
Analysis of cytokine production
Cytokine production was analyzed with the ProcartaPlex Luminex assay
(Ebioscience) containing the non-human primates IL-2, IL-23p19, IL-12p70
and IFN-γ, and the human IL-17A beads (bead numbers 19, 63, 34, 43 and 36,
respectively). Brieﬂy, 0.5 million MNCs (N= 8 marmosets) were plated with
equal number of B-LCL (1:1) in 0.5 ml of media as described above. Following
24 and 48 h of incubation at 37 °C, supernatants were isolated and stored at
− 20 °C. The Luminex multiplex assay was performed according to manufac-
turer’s protocol and results were analyzed with the BioPlex 200 system
(Bio-Rad, Hercules, CA, USA). Data were quantiﬁed based on manufacturer
standards reconstituted in cell culture media.
RNA sequencing
RNA sequencing was performed on spleen-derived CD20+ B cells isolated from
healthy marmosets (n= 2) and B-LCLs (n= 2). Brieﬂy, whole spleen homo-
genates from healthy control monkeys were stained with phycoerythrin labeled
CD20 (B1-RD1; Beckman Coulter) and Horizon V500-labeled CD3 as
described above. FACS-sorted CD3−CD20+ were stored as dry pellets at
− 80 °C.
RNA was isolated from CD3−CD20+ spleen cells and marmoset B-LCLs.
Illumina HiSeq 2500 single-end RNA sequencing was performed at the
Department of Genetics of the UMCG Groningen. For quality control,
FASTQC was performed.64 Low-quality reads were trimmed with FASTX
trimmer (Version 0.0.14).65 The hisat/0.1.5-beta-goolf-1.7.20 alignment66 was
performed using Callithrix jacchus GRCm38.82 reference genome. Approxi-
mately 10 million high-quality uniquely mapped reads were obtained per
sample. HT-seq count67 was utilized to quantify reads, which were imported
into R (version 3.2.3) to be statistically analyzed for differential gene expression
using EdgeR.68 Gene annotation and gene ontology data of the ensemble data
were obtained using the R Biomart Bioconductor tool.69 A heatmap of log
count per million values was generated using heatmap.2. Functional and
pathway annotation of the differentially expressed genes was performed using
Gene Ontology and Kegg from DAVID.70,71
Statistics
Statistical analysis was performed using Prism 6.0b for Mac OS X. Data were
analyzed using the two-tailed paired Student’s t-test (Wilcoxon). P-valueso0.05
were considered statistically signiﬁcant. Data are shown as individual values
(n= 14), although experiments were performed separately due to the variation
in date of animal sacriﬁce. Error bars represent s.e.m.
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